Concomitant use of losartan with fenofibrate is beneficial in the treatment of patients with gout and hypertriglyceridemia.
Losartan shows no effect on the pharmacokinetics of warfarin and digoxin.
Administration of losartan with fluconazole, phenytoin and grapefruit juice inhibits the metabolism of losartan to its active metabolite. Although not yet established, the possibility of decreased therapeutic effect of losartan may be considered.
Rifampicin was found to induce the metabolism of losartan to its active metabolite, E3174 thereby, reducing levels of both losartan and E3174 in the circulation.
Losartan does not affect the pharmacokinetic properties of phenytoin and orlistat.
Administration of losartan with spironolactone and other potassium-sparing diuretics may lead to the occurrence of hyperkalemia. Physicians are advised to monitor patient's serum potassium level.
The use of losartan with ACE inhibitors and β-blockers potentiates the antihypertensive effects of losartan.
There have been reports of lithium intoxication when losartan was given to patients treated with lithium.
                                
                            Other Services
                            
                            
                            Country
                            Account
                            
                         
 
            
 
         
                 
                                     
                             
                                             
                                             Sign Out
 Sign Out
                                     
                                             
                                             
                                            